Roche's much-hyped multiple sclerosis treatment ocrelizumab kept up its momentum with the release of detailed late-stage data, burnishing hopes the injected drug is a blockbuster in the making.
Remote patient monitoring isn't a core business for Boston Scientific, but it is looking to gain access to the most cutting-edge tech in the field. It's launched the Boston Scientific Connected Patient Challenge: an open innovation challenge to solicit ideas and collaborations for remote patient monitoring.
The Wyss Institute for Biologically Inspired Engineering at Harvard University has launched startup Opsonix to develop its pathogen-extracting, extracorporeal sepsis device. Hansjörg Wyss, who founded the Institute with a $125 million gift in 2008, also participated in an $8 million Series A round that was led by Baxter Ventures.
INC Research added a new tool for early-stage safety studies, bringing in a new technology the company says will make Phase I cardiac trials more efficient.
Critics have long questioned the effectiveness of Roche and GlaxoSmithKline's flu drugs, asking whether their benefits justify the estimated $2 billion spent to stockpile them for potential epidemics. Now, heading into flu season, scientists have an answer: No one knows.
Privately held CRO PPD scored two federal contracts tasking it with helping to improve health outcomes for active-duty soldiers and aiding with the government's stockpile of flu vaccines.
Harvard's Wyss Institute is spinning out another biotech. The cutting-edge research group has launched Opsonix with $8 million from Baxter Ventures and Hansjörg Wyss, the Swiss billionaire who founded the institute.
Genae, a med tech-focused CRO, opened a Japanese outpost to broaden its reach, setting up shop in Tokyo with eyes on the growing Asian market for medical devices.
German drug developer Evotec signed a 5-year, $4.9 million agreement with the National Cancer Institute to help the group build and manage its library of potential oncology drugs.
As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.